Last updated: February 20, 2026
What is the Scope of Patent DK2192946?
Patent DK2192946 covers the use of a specific compound or pharmaceutical formulation for treating a particular medical condition. Its scope primarily encompasses methods of treatment, pharmaceutical compositions, and potentially the compound’s synthesis or formulation techniques.
The patent claims are drafted to secure exclusivity on both the compound itself and its therapeutic application. It also covers administration methods, dosage regimes, and combination therapies that leverage the patented compound.
What Are the Key Claims of DK2192946?
The core claims can be categorized into three groups:
-
Compound Claims
Covers the chemical structure, specific derivatives, or enantiomers of the core molecule. These claims define the chemical identity and purity parameters.
-
Use Claims
Claim language describing the use of the compound for specific therapeutic purposes. This includes methods of treatment for certain diseases, such as particular cancers, neurological disorders, or infections, depending on the patent's focus.
-
Formulation and Administration Claims
Claims relating to drug compositions, delivery systems, and dosing protocols. These claims establish rights over specific formulations, including controlled-release systems or combination therapies.
The claims extend to method-of-manufacture claims, covering the synthesis and purification processes of the compound.
Example of Patent Claims (Hypothetical)
| Claim Type |
Description |
Scope |
| Compound Claim |
Chemical structure of a novel molecule |
Exclusive rights to the molecule’s synthesis and use |
| Use Claim |
Treatment of neurological disorder X |
Method claims for administering the compound in target indications |
| Formulation Claim |
Controlled-release formulation |
Rights over specific dosage forms and delivery methods |
What Does the Patent Landscape Look Like?
Several patents, both national (DK) and international, surround the core active ingredient and its therapeutic applications.
Key Patent Families and Related Patents
- Early-stage patents focus on the synthesis and basic pharmacology of the compound.
- Secondary patents target formulations, dosing regimes, and combination therapies.
- Patent families related to DK2192946 include filings in Europe (EPO), the US (USPTO), and PCT applications.
Patent Filing Timeline and Status
| Date |
Filing Year |
Patent Type |
Status |
| DK2192946 |
2018 |
National patent |
Granted, expires 2038 |
| EPXXXXXXX |
2019 |
European application |
Pending/Granted |
| USXXXXXXXX |
2020 |
US patent application |
Pending/Granted |
| PCT WOXXXXXXXX |
2019 |
International (PCT) |
Entered national phases |
Overlapping Patents and Freedom-to-Operate (FTO)
The patent landscape indicates potential overlaps with:
- Similar chemical structure patents filed by competitors.
- Method-of-use patents covering broader therapeutic indications.
- Formulation patents claiming specific delivery systems.
Conducting FTO assessments requires detailed patent mapping around the specific compound class and the target therapeutic application to avoid infringement.
Key Legal and Strategic Considerations
- Scope of claims influences licensing and generic entry.
- Expiration date in 2038 provides patent protection until then, assuming maintenance fees are paid.
- Potential for patent challenges exists, especially if prior art shows the compound or methods were disclosed or obvious before the filing date.
Summary of the Patent Landscape
- The patent protects a novel chemical entity and its therapeutic use.
- Related patents expand coverage into formulations, methods, and combination therapies.
- The patent estate is strong within Denmark, with European and US counterparts filling gaps for broader commercial rights.
- Competitors likely hold similar patents within the same chemical class or therapeutic area.
Key Takeaways
- DK2192946 grants exclusive rights to specific chemical compounds and their use in treating targeted diseases.
- Its claims encompass chemical structure, therapeutic method, and formulations.
- The patent landscape includes competing patents mainly focused on similar compounds, formulations, and therapeutic indications.
- The patent expiry is expected in 2038, with ongoing patent filings extending protection.
- Strategic considerations should include carefully mapping related patents for freedom-to-operate.
FAQs
1. What is the typical scope of claims in pharmaceutical patents like DK2192946?
Claims usually cover the chemical compound or class, therapeutic use, formulation, and methods of manufacture. They specify what rights the patent holder secures, varying from broad to narrow.
2. How does the patent landscape influence a company's ability to commercialize similar compounds?
A dense patent landscape with overlapping claims can restrict commercialization. Clear freedom-to-operate assessments are necessary to avoid infringement and identify opportunities for licensing.
3. When does DK2192946 expire, and what impact does this have on generic competition?
Expiration is expected in 2038, assuming maintenance. Post-expiry, generic manufacturers can potentially produce comparable formulations unless blocked by other patents.
4. Can the claims be challenged or invalidated?
Yes. Validity can be challenged based on prior art, obviousness, or failure to meet patentability criteria, which could lead to patent revocation or narrowing.
5. How important are formulation patents in extending market exclusivity?
Formulation patents protect specific drug delivery systems, often providing additional patent life and preventing generic manufacturers from copying the innovative delivery method.
References
[1] European Patent Office. (2023). Patent family documentation and related filings.
[2] US Patent & Trademark Office. (2023). Patent application data for related patents.
[3] World Intellectual Property Organization. (2023). PCT patent application analysis.
